WestVac Biopharma Co.,Ltd.
Chengdu, China (ots/PRNewswire)
CHENGDU, China, June 9, 2023 /PRNewswire/– On June 8, 2023, Coviccine® Trivalent XBB.1.5 Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell) , developed by WestVac Biopharma/West China Medical Center and Sichuan University, has been approved by the relevant authorities in China under an EUA Emergency Use Authorization. This is the world‘s first COVID-19 vaccine to receive EUA (Emergency Use Authorization) against XBB descendants of SARS-CoV-2. It shows that China is a world leader in developing COVID-19 vaccines.
WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) leveraged the fast response of the insect cell expression platform in the construction of the vector for Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1,5+BA.5+ Delta) protein vaccine (Sf9 cell) which is of high purity and high quality for human use. The subunit vaccine antigen is designed based on the exact structure of the targeted S-RBD and HR proteins of COVID-19 subvariants XBB.1.5 and BA.5 and self-assembled into trimmer protein particles with a squalene-based oil-in-water emulsion adjuvant , which is added after purification and mixing. This novel adjuvant significantly elevates the titer of neutralizing antibodies, allowing the trimmer protein vaccine to induce a higher T cell immune response. Studies have shown that Coviccine® Trivalent XBB.1.5 induces high titers of neutralizing antibodies against multiple subvariants including omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75. 14 days after injection of this product, the protective efficacy against XBB.1, XBB.1.5, XBB1.9 is 93.28% with an excellent safety profile, proving that it was a broad spectrum COVID-19 vaccine against multiple locally and internationally spread subvariants.
The XBB.1.5 variant had gradually become the main circulating variant in various parts of the world by early 2023. With professional guidance and support from the Vaccine R&D team of the State Council Joint Prevention and Control Mechanism, the scientific team of WestVac Biopharma/West China Medical Center, Sichuan University overcame all the hurdles and successfully developed a vaccine for the XBB variant family.
In early May, a Chinese CDC expert found that the XBB variants are much more highly transmitted and able to evade the immune system than the early Omicron variants. The lineages descended from XBB.1 currently dominate the worldwide circulation of SARS-CoV-2. At the end of May, XBB family variants accounted for 98.1% of all variants in the United States. In China, the number of newly discovered XBB variants has gradually increased and is now over 90%.
The WHO COVID-19 Vaccine Composition Technical Advisory Group (TAG-CO-VAC) on May 18 indicated that new formulations of COVID-19 vaccines should aim to induce antibody responses that neutralize XBB offspring. The rate of “second infection” is increasing. Experts strongly advise immediate prevention and vaccination against COVID-19, especially for people at high risk, the elderly, people with underlying (pre-)illnesses and those who are immunologically compromised to receive a vaccine against SARS-CoV-2- get variants.
WestVac Biopharma is using the international advanced insect cell recombinant protein vaccine platform to develop Coviccine® Trivalent XBB.1.5, which has received EUA (Emergency Use Authorization) in China. WestVac’s COVID-19 vaccine offers a unique option for COVID-19 prevention, is critical to the prevention of the current XBB progeny, and is a major contributor to ongoing management with the COVID-19 epidemic.
About WestVac Biopharma
WestVac BioPharma Co.,Ltd. is an innovative biopharmaceutical company capable of conducting the full spectrum of research, manufacturing and commercialization of products. WestVac Biopharma has been successfully named to the 2021-2023 Unicorn Companies list. WestVac BioPharma Co.,Ltd. is based in western China, while WestVac Biopharma (Guangzhou), a wholly owned subsidiary of WestVac Biopharma, is located in Guangzhou Economic Development Zone.
WestVac BioPharma Co.,Ltd. has completed the construction of 5,000 and 3,000 liter production lines of recombinant protein vaccines in islet cells with an annual production capacity of 100 million doses. The GMP production lines were well established with the “Drug Production License” in force. WestVac Biopharma (Guangzhou) has completed the construction of production lines for recombinant insect cell-derived protein vaccines with an annual production capacity of 100 million doses.
Photo – https://mma.prnewswire.com/media/2097401/2.jpg
Original content from: WestVac Biopharma Co.,Ltd., transmitted by news aktuell